What's new

Human medicines European public assessment report (EPAR): Absimky, ustekinumab, Date of authorisation: 12/12/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Absimky, ustekinumab, ...

Human medicines European public assessment report (EPAR): NovoRapid, insulin aspart, Date of authorisation: 07/09/1999, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): NovoRapid, insulin asp...

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Da...

Nitrosamine impurities: guidance for marketing authorisation holders

Nitrosamine impurities: guidance for marketing authoris...

May 28, 2025 0

Nitrosamine impurities: guidance for marketing authorisation holders

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Da...

Human medicines European public assessment report (EPAR): Efficib, sitagliptin,metformin, Date of authorisation: 15/07/2008, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Efficib, sitagliptin,m...

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Truxima, rituximab, Da...

Human medicines European public assessment report (EPAR): Privigen, human normal immunoglobulin (IVIg), Date of authorisation: 24/04/2008, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Privigen, human normal...

Human medicines European public assessment report (EPAR): Pemetrexed medac, pemetrexed, Date of authorisation: 26/11/2015, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Pemetrexed medac, peme...

Champix

May 28, 2025 0

Champix

Human medicines European public assessment report (EPAR): Lacosamide Accord, lacosamide, Date of authorisation: 18/09/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Lacosamide Accord, lac...

Human medicines European public assessment report (EPAR): Cubicin, daptomycin, Date of authorisation: 19/01/2006, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Cubicin, daptomycin, D...

Human medicines European public assessment report (EPAR): Sixmo, buprenorphine, Date of authorisation: 19/06/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Sixmo, buprenorphine, ...

Quality of medicines questions and answers: Part 2

Quality of medicines questions and answers: Part 2

May 28, 2025 0

Quality of medicines questions and answers: Part 2

Scientific and technical recommendations: Veterinary Medicines Regulation

Scientific and technical recommendations: Veterinary Me...

May 28, 2025 0

Scientific and technical recommendations: Veterinary Medicines Regulation

Minutes of the CHMP meeting 27-30 January 2025

May 28, 2025 0

Minutes of the CHMP meeting 27-30 January 2025

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab d...

Human medicines European public assessment report (EPAR): Emgality, galcanezumab, Date of authorisation: 14/11/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Emgality, galcanezumab...

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, ...

Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Date of authorisation: 17/06/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Adtralza, tralokinumab...

Annex to 27-30 January 2025 CHMP Minutes

May 28, 2025 0

Annex to 27-30 January 2025 CHMP Minutes

PSUSA/00000210/202408

PSUSA/00000210/202408

May 28, 2025 0

PSUSA/00000210/202408

PSUSA/00001603/202408

PSUSA/00001603/202408

May 28, 2025 0

PSUSA/00001603/202408

Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025 0

Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Da...

1
2
3

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.